Reviva Pharmaceuticals (RVPH) Lytham Partners Spring 2025 Investor Conference summary

Pipeline and therapeutic focus

• Two molecules in development, with Brilaroxazine as the lead candidate in phase III for schizophrenia and potential for expansion into bipolar disorder, major depressive disorder, ADHD, and inflammatory conditions like pulmonary hypertension and psoriasis.

• Brilaroxazine demonstrated anti-inflammatory effects and is positioned for large market indications, especially where psychiatric and inflammatory comorbidities overlap.

Unmet needs and current treatment landscape

• Schizophrenia affects over 24 million globally, with 30% of patients not responding or only partially responding to current antipsychotics.

• Major unmet needs include addressing negative symptoms and improving treatment adherence, as current drugs show high discontinuation rates (32%-45% in acute, ~70% in long-term).

Clinical trial results and efficacy

• Brilaroxazine showed 12%-16% discontinuation in acute trials and 35% in long-term, about 50% better adherence than existing treatments.

• Phase III trial (411 patients) showed a 10-point separation from placebo on the primary endpoint, with early onset and sustained improvement.

• Statistically significant efficacy for negative symptoms, with a two-point separation and even greater effect (3.7 reduction) in patients with severe negative symptoms.

• Digital biomarkers (speech patterns) and blood-based biomarkers confirmed robust efficacy, especially in high-severity subgroups.